Latest news with #RM52.9mil

The Star

Alpha IVF sets up second facility in the Philippines

PETALING JAYA: Alpha IVF Group Bhd is establishing a new full-fledged fertility treatment centre in Tuguegarao, the Philippines, marking the group's second planned facility in the country. In a statement, the fertility care specialist said the new centre advances the group's mission to broaden access to assisted reproductive services across the region. Alpha IVF said the centre would provide minimally invasive surgery in gynaecology, which is expected to contribute significantly to the centre's revenue. 'Tuguegarao, a rapidly developing urban hub in northern Luzon, has a substantially underserved healthcare sector, with a growing middle-income demographic and a catchment population of 23.2 million, our centre will be the first and only IVF facility in the northern half of Luzon – Philippines' most populous island – positioning us to meet the increasing demand for advanced fertility care. 'The upcoming centre, targeted to be operational by the fourth quarter of 2026 (4Q26), will strategically complement the group's upcoming centre in Manila, to be launched by October 2025, as it grows its footprint in the Philippines,' the company said. Group managing director Datuk Dr Colin Lee Soon Soo said the expansion into Tuguegarao allowed the company 'to make a tangible difference where demand for fertility treatment is significant, but access is limited.' 'Our mission is to bridge these accessibility gaps, reflecting our disciplined approach to investing in strategic locations that allow us to deliver world-class care, empowering more families across South-East Asia to achieve their dream of parenthood,' he added. Separately Alpha IVF announced that it achieved its highest-ever profit after tax and minority interests (patmi) of RM57.5mil in the financial year ended May 31, 2025 (FY25) – a 8.5% increase from RM52.9mil in the previous year. 'The strong bottom-line performance was supported by revenue growth of 5.5% to RM176.8mil in FY25 from RM167.6mil in the previous year, led by the group's Malaysia operations, particularly the foreign patient segment.' The company said Malaysia operations contributed RM157.2mil, or 88.9% of the group's total revenue in FY25 – a 16% increase from RM135.5mil in the previous year, or 80.9% of the group's total revenue. The group's Singapore operations contributed the remaining RM19.6mil, according to the statement. In the fourth quarter ended May 31, 2025, the group's revenue rose 7% year-on-year to RM50mil from RM46.7mil previously, while patmi saw a 14.7% increase to RM16.1mil from RM14mil in the corresponding quarter of the previous year. The group has declared a second interim dividend of 0.50 sen per share in respect of FY25, payable on Aug 29. 'Together with the first interim dividend of 0.50 sen per share paid on Dec 31, 2024, the total dividends for FY25 amount to one sen per share, representing a payout of RM48.6mil or 84.6% of patmi. 'This is well above the group's commitment to distribute at least 60% of its annual patmi for shareholders.'